ANKTIVA®
Clinical Trials
Find a Trial
Become a Trial
Investigator
License our Cells
Science
Platforms
Pipeline
Expanded Access
Research
Approach
Patients
Trial Investigators
Researchers
Condition
Bladder Cancer
Glioblastoma
HIV
Lynch / Colon Cancer
Non-Hodgkin Lymphoma
Human Papillomavirus
Non-Small Cell Lung Cancer
Company
About Us
Investors
News and Events
Contact
Careers
Founder’s Vision
Cancer Moonshot 2020
Childhood Cancer – Sen. McCain
Cancer Moonshot Announcement
Formation of ImmunityBio
Select Page
Feb 18, 2022
| Uncategorized
Search for:
Recent Posts
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
JPM Healthcare Conference
ASCO GI
ASCO GU
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
